CommentaryVideo共7篇
Recent Progress in Advancing Gene Therapy for Parkinson Disease: Russell Lonser, MD-爱医学

Recent Progress in Advancing Gene Therapy for Parkinson Disease: Russell Lonser, MD

WATCH TIME: 4 minutes'I think what gene therapy provides us is a new opportunity to really target the specific problem of the disease at its core.'AB-1005 (AskBio), an investigatio...
eason的头像-爱医学eason8个月前
390
Navigating Challenges and Opportunities With AI Adoption in Neurological Practice: Lidia Maria Veras Rocha Moura, MD, PhD, MPH, FAAN-爱医学

Navigating Challenges and Opportunities With AI Adoption in Neurological Practice: Lidia Maria Veras Rocha Moura, MD, PhD, MPH, FAAN

WATCH TIME: 5 minutes'What I really wanted to highlight is that we should be thinking about equity, and access. Many solutions might have the ability to increase clinician efficien...
eason的头像-爱医学eason8个月前
380
Cell-Based Therapies and Bembaneprocel-爱医学

Cell-Based Therapies and Bembaneprocel

At the 2024 American Academy of Neurology Annual Meeting, NeurologyLive® sat down with Parkinson disease (PD) expert Daniel Kremens, MD, JD, to discuss some of the top data being ...
eason的头像-爱医学eason8个月前
240
Closing Thoughts and Outlook of PD Care-爱医学

Closing Thoughts and Outlook of PD Care

At the 2024 American Academy of Neurology Annual Meeting, NeurologyLive® sat down with Parkinson disease (PD) expert Daniel Kremens, MD, JD, to discuss some of the top data being ...
eason的头像-爱医学eason8个月前
270
Early Treatment Response and Safety Profile of AXS-05 in Phase 3 ACCORD Trial: Anton P. Porsteinsson, MD-爱医学

Early Treatment Response and Safety Profile of AXS-05 in Phase 3 ACCORD Trial: Anton P. Porsteinsson, MD

WATCH TIME: 6 minutes'It's important because when patients finally seek treatment for agitation and aggression that’s been going on for quite a while and has gotten to a critical ...
eason的头像-爱医学eason8个月前
320
PrimeC Performs Well in High-Risk ALS, Patient Death Reported in DAYLIGHT Trial, Donanemab AdComm Hearing Date Announced-爱医学

PrimeC Performs Well in High-Risk ALS, Patient Death Reported in DAYLIGHT Trial, Donanemab AdComm Hearing Date Announced

WATCH TIME: 4 minutesWelcome to this special edition of Neurology News Network. I’m Marco Meglio.Newly announced analyses from the phase 2b PARADIGM trial showed that treatment wi...
eason的头像-爱医学eason8个月前
240
Overlooked Neurological Features Present in Long COVID: Svetlana Blitshteyn, MD, FAAN-爱医学

Overlooked Neurological Features Present in Long COVID: Svetlana Blitshteyn, MD, FAAN

WATCH TIME: 3 minutes'For many years, those of us who specialize in these disorders have seen patients with very similar features that the patients with Long COVID have. Many of th...
eason的头像-爱医学eason8个月前
260